The CX3C-Chemokine Fractalkine in Kidney Diseases

E-ISSN： 1875-5607|9|10|1215-1228

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.9, Iss.10, 2009-01, pp. : 1215-1228

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential

By D'Haese Jan G Demir Ihsan Ekin Friess Helmut Ceyhan Güralp O

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 2, 2010-02 ,pp. : 207-219

Informa Healthcare

Access to resources Recommend Favorite

Functional expression of the fractalkine (CX 3 C) receptor and its regulation by lipopolysaccharide in rat microglia

By Boddeke E.W.G.M. Meigel I. Frentzel S. Biber K. Renn L.Q. Gebicke-Harter P.

European Journal of Pharmacology, Vol. 374, Iss. 2, 1999-06 ,pp. : 309-313

Elsevier

Access to resources Recommend Favorite

Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 10, 2011-10 ,pp. : 1707-1714

Bentham Science Publishers

Access to resources Recommend Favorite

CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?

Current Gene Therapy, Vol. 17, Iss. 6, 2018-03 ,pp. : 442-452

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 11, 2007-11 ,pp. : 1089-1096

Bentham Science Publishers

Access to resources Recommend Favorite